Molecular Diagnostics - Technologies, Markets and Companies

September 2010. 969 Pages, US$5,000 (electronic)

Benefits of this report
Who should read this report?
Summary
Table of contents
Ordering information
Inquiries

Benefits of this report

This report has evolved during the past 15 years, profiting from feedback by numerous readers and experts.
The most comprehensive and up-to-date one-stop source of information on technical and commercial aspects of molecular diagnostics.
Includes profiles of 295 companies, the largest number in any report on this topic.
500 references, cited in the report are included in the bibliography.
The text is supplemented by 92 tables and 15 figures.

Who should read this report?

Chief executive officers of molecular diagnostic companies.
Business development executives of pharmaceutical and biotechnology companies.
Executives of companies involved in developing integration of diagnosis and treatment as well as those interested in personalized medicine.
Officers of genomic and proteomic companies interested in diagnostic technologies.
Research scientists involved in application of molecular diagnostic technologies.
Planners of healthcare services.

This report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, biochips, nanotechnology and proteomic technologies.

Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. Genetic screening tests, despite some restrictions is a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare. Molecular diagnostic technologies are also involved in development of personalized medicine based on pharmacogenetics and pharmacogenomics. Currently, there has been a considerable interest in developing rapid diagnostic methods for for point-of-care and biowarfare agents such as anthrax.

The number of companies involved in molecular diagnostics has increased remarkably during the past few years. More than 500 companies have been identified to be involved in develop63ing molecular diagnostics and 295 of these are profiled in the report along with tabulation of 657 collaborations. Despite the strict regulation, most of the development in molecular diagnostics has taken place in the United States, which has the largest number of companies.

The markets for molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with markets for non-molecular diagnostic technologies in the in vitro diagnostic market and are less well defined than those for pharmaceuticals. Molecular diagnostic markets are analyzed for 2009 according to technologies, applications and geographical regions. Forecasts are made up to 2019. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics.

This report was first published as DNA Diagnostics in 1995 by PJB Publications, UK. It was updated in 1997 as Molecular Diagnostics and the next edition, Molecular Diagnostics II, was published by Decision Resources Inc in 1999. All the three versions of the reports were well accepted and sold widely.The report has been rewritten several times since then.